Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus

Diabetic Medicine

Volumn 31, Issue 9, 2014, Pages 1138-1147

  Pena, M J ^a   Lambers Heerspink, H J ^a   Hellemons, M E ^a   Friedrich, T ^b   Dallmann, G ^b   Lajer, M ^c   Bakker, S J L ^a   Gansevoort, R T ^a   Rossing, P ^c,d,e   de Zeeuw, D ^a   Roscioni, S S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BIOCRATES LIFE SCIENCES AG   (Austria)

^c STENO DIABETES CENTER   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE; HEXOSE; HISTIDINE; TYROSINE; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; AGED; ALBUMINURIA; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; MICROALBUMINURIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; URINALYSIS; CASE CONTROL STUDY; EARLY DIAGNOSIS; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EARLY DIAGNOSIS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 84906224684     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12447     Document Type: Article

References (36)

1. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
2. Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27: 1897-1903.
3. Viazzi F, Leoncini G, Conti N, Tomolillo C, Giachero G, Vercelli M et al. Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC study. Clin J Am Soc Nephrol 2010; 5: 1099-1106.
4. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821.
5. Zhao YY, Cheng XL, Wei F, Bai X, Tan XJ, Lin RC et al. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-beta1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MS(E). J Proteome Res 2013; 12: 692-703.
6. Zhao YY. Metabolomics in chronic kidney disease. Clin Chim Acta 2013; 422: 59-69.
7. Shah VO, Townsend RR, Feldman HI, Pappan KL, Kensicki E. Vander Jagt DL. Plasma metabolomic profiles in different stages of CKD. Clin J Am Soc Nephrol 2013; 8: 363-370.
8. Hirayama A, Nakashima E, Sugimoto M, Akiyama S, Sato W, Maruyama S et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem 2012; 404: 3101-3109.
9. Zhang J, Yan L, Chen W, Lin L, Song X, Yan X et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta 2009; 650: 16-22.
10. Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013; 24: 1901-1912.
11. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 2000; 11: 1882-1888.
12. Reinhard H, Hansen PR, Persson F, Tarnow L, Wiinberg N, Kjaer A et al. Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant 2011; 26: 3242-3249.
13. Roscioni SS, de Zeeuw D, Hellemons ME, Mischak H, Zurbig P, Bakker SJ, et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2013; 56: 259-267.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
15. Solberg R, Enot DP, Deigner HP, Koal T, Scholl-Bürgi S, Saugstad OD et al. Metabolomic analysis of plasma reveals new insights into asphyxia and resuscitation in pigs. PLoS One 2010; 5: e9606.
16. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for industry bioanalytical method validation. 2011.
17. Johnson WE, Rabinovic A, Li C. Adjusting batch effect in microarray expression data using Empirical Bayes methods. Biostatistics 2007; 8: 118-127.
18. Smyth G. Linear models and emprical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 1-26.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
21. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-336.
22. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity 2010; 18: 1695-1700.
23. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-2950.
24. Van der Kloet FM, Tempels FWA, Ismail N, van der Heijden R, Kasper PT, Rojas-Cherto M et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 2012; 8: 109-119.
25. Goek ON, Döring A, Gieger C, Heier M, Koenig W, Prehn C et al. Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis 2012; 60: 197-206.
26. Van Slyke DD, Phillips RA, Hamilton PB, Archibald RM, Flucher PH, Hiller A. Glutamine as source material of urinary ammonia. J Biol Chem 1943; 150: 481-482.
27. Babizhayev MA, Seguin MC, Gueyne J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA. L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem J 1994; 304: 509-516.
28. Watanabe M, Suliman ME, Qureshi AR, Garcia-Lopez E, Barany P, Heimburger O et al. Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. Am J Clin Nutr 2008; 87: 1860-1866.
29. Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC. Histidine and carnosine delay diabetic, deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 2005; 513: 145-150.
30. Shao N, Kuang HY, Wang N, Gao XY, Hao M, Zou W et al. Relationship between oxidant/antioxidant markers and severity of microalbuminuria in the early stage of nephropathy in Type 2 diabetic patients. J Diabetes Res 2013; 2013: 1-6.
31. Kopple JD. Phenylalanine and tyrosine metabolism in chronic kidney failure. J Nutr 2007; 137: 1586S-1590S.
32. Werner ER, Blau N, Thoeny B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 2011; 438: 397-414.
33. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17: 448-453.
34. Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr 2011; 2: 445-456.
35. Suliman ME, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Barany P, Heimburger O et al. Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am J Clin Nutr 2005; 82: 342-349.
36. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008; 51: 714-725.